Lux names Dean Mitchell as new CEO; Martek cuts 45 jobs; Sanofi wins an orphan drug designation;

@FierceBiotech: On a buying spree, Sanofi scoops up TargeGen in $635M deal. Article | Follow @FierceBiotech

@JohnCFierce: The prospect of add-on approvals could make quite a difference on the revenue side. Celgene certainly can do better than Abraxis alone. | @JohnCFierce

> Jersey City, NJ-based Lux Biosciences has named Dean Mitchell, the former CEO of Alpharma, as its president and CEO. Lux release

> Martek Biosciences plans to cut 45 manufacturing jobs in Kentucky. Story

> The European Commission for the Treatment of Tuberculosis has provided orphan drug status to Sanofi's rifapentine. Sanofi release

> A struggling Cell Therapeutics has told analysts that it has deposited enough money to cover its convertible debt through this year. Its share price rose three cents to 41 cents a share. Story

And Finally... Seattle-based Theraclone Sciences says that a team of scientists in its own ranks working in league with colleagues from around the world have zeroed in on rare antibodies that have the ability to latch on to a piece of the flu virus that's common to a wide variety of strains. Report

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.